Article Versions Notes

Chung CH, Bonomi M, Steuer CE, Li J, Bhateja P, Johnson M, Masannat J, Song F, Hernandez-Prera JC, Wenig BM, et al. Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study. Cancers. 2021; 13(5):1180. https://doi.org/10.3390/cancers13051180

Chung, Christine H., Marcelo Bonomi, Conor E. Steuer, Jiannong Li, Priyanka Bhateja, Matthew Johnson, Jude Masannat, Feifei Song, Juan C. Hernandez-Prera, Bruce M. Wenig, and et al. 2021. "Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study" Cancers 13, no. 5: 1180. https://doi.org/10.3390/cancers13051180

Chung, C. H., Bonomi, M., Steuer, C. E., Li, J., Bhateja, P., Johnson, M., Masannat, J., Song, F., Hernandez-Prera, J. C., Wenig, B. M., Molina, H., Farinhas, J. M., McMullen, C. P., Wadsworth, J. T., Patel, K. B., Kish, J. A., Muzaffar, J., Kirtane, K., Rocco, J. W., ... Saba, N. F. (2021). Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study. Cancers, 13(5), 1180. https://doi.org/10.3390/cancers13051180